The cell fate determinant Numb is frequently downregulated in human breast cancers (BCs), resulting in p53 inactivation and an aggressive disease course. In the mouse mammary gland, Numb/p53 downregulation leads to aberrant tissue morphogenesis, expansion of the stem cell compartment, and emergence of cancer stem cells (CSCs). Strikingly, CSC phenotypes in a Numb-knockout mouse model can be reverted by Numb/p53 restoration. Thus, targeting Numb/p53 dysfunction in Numb-deficient human BCs could represent a novel anti-CSC therapy. Here, using patient-derived xenografts, we show that expansion of the CSC pool, due to altered self-renewing divisions, is also a feature of Numb-deficient human BCs. In these cancers, using the inhibitor Nutlin-3 to restore p53, we corrected the defective self-renewal properties of Numb-deficient CSCs and inhibited CSC expansion, with a marked effect on tumorigenicity and metastasis. Remarkably, a regimen combining Nutlin-3 and chemotherapy induced persistent tumor growth inhibition, or even regression, and prevented CSC-driven tumor relapse after removal of chemotherapy. Our data provide a pre-clinical proof-of-concept that targeting Numb/p53 results in a specific anti-CSC therapy in human BCs.

Pre-clinical validation of a selective anti-cancer stem cell therapy for Numb-deficient human breast cancers / D. Tosoni, S. Pambianco, B. Ekalle Soppo, S. Zecchini, G. Bertalot, G. Pruneri, G. Viale, P.P. Di Fiore, S. Pece. - In: EMBO MOLECULAR MEDICINE. - ISSN 1757-4676. - 2017(2017 Mar 15), p. e201606940. [Epub ahead of print]

Pre-clinical validation of a selective anti-cancer stem cell therapy for Numb-deficient human breast cancers

S. Zecchini;G. Pruneri;G. Viale;P.P. Di Fiore
;
S. Pece
2017

Abstract

The cell fate determinant Numb is frequently downregulated in human breast cancers (BCs), resulting in p53 inactivation and an aggressive disease course. In the mouse mammary gland, Numb/p53 downregulation leads to aberrant tissue morphogenesis, expansion of the stem cell compartment, and emergence of cancer stem cells (CSCs). Strikingly, CSC phenotypes in a Numb-knockout mouse model can be reverted by Numb/p53 restoration. Thus, targeting Numb/p53 dysfunction in Numb-deficient human BCs could represent a novel anti-CSC therapy. Here, using patient-derived xenografts, we show that expansion of the CSC pool, due to altered self-renewing divisions, is also a feature of Numb-deficient human BCs. In these cancers, using the inhibitor Nutlin-3 to restore p53, we corrected the defective self-renewal properties of Numb-deficient CSCs and inhibited CSC expansion, with a marked effect on tumorigenicity and metastasis. Remarkably, a regimen combining Nutlin-3 and chemotherapy induced persistent tumor growth inhibition, or even regression, and prevented CSC-driven tumor relapse after removal of chemotherapy. Our data provide a pre-clinical proof-of-concept that targeting Numb/p53 results in a specific anti-CSC therapy in human BCs.
numb; breast cancer; cancer stem cells; p53; primary‐derived xenografts
Settore MED/04 - Patologia Generale
Settore MED/08 - Anatomia Patologica
15-mar-2017
15-mar-2017
Article (author)
File in questo prodotto:
File Dimensione Formato  
01 Tosoni et al emmm.pdf

accesso aperto

Descrizione: Article
Tipologia: Publisher's version/PDF
Dimensione 2.31 MB
Formato Adobe PDF
2.31 MB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/486820
Citazioni
  • ???jsp.display-item.citation.pmc??? 22
  • Scopus 31
  • ???jsp.display-item.citation.isi??? 30
social impact